Last reviewed 2026-04-20 · How we verify

Pandrocine (PENMESTEROL)

Phase 2 active Small molecule

Pandrocine (generic name: PENMESTEROL) is a penmesterol drug. It is currently in Phase 2 development.

Pandrocine works by interacting with a specific molecular target to produce a therapeutic effect.

Pandrocine, also known as Penmesterol, is a small molecule drug of the penmesterol class. Unfortunately, there is limited information available on this compound. As a result, I am unable to provide a comprehensive summary. Further research is needed to determine its target, approved indications, and commercial status. It is not clear if it is patented or available as a generic.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PENMESTEROL
Drug class	penmesterol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Pandrocine has a key that fits into those locks. When it binds to the lock, it triggers a series of events that help to treat a particular condition. This is a simplified explanation of how Pandrocine works at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pandrocine CI brief — competitive landscape report
Pandrocine updates RSS · CI watch RSS

Frequently asked questions about Pandrocine

What is Pandrocine?

Pandrocine (PENMESTEROL) is a penmesterol drug.

How does Pandrocine work?

Pandrocine works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Pandrocine?

PENMESTEROL is the generic (nonproprietary) name of Pandrocine.

What drug class is Pandrocine in?

Pandrocine belongs to the penmesterol class. See all penmesterol drugs at /class/penmesterol.

What development phase is Pandrocine in?

Pandrocine is in Phase 2.

Drug class: All penmesterol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing